Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Context Therapeutics (NASDAQ: CNTX)The analyst comments "We are initiating the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE